Discover
llllllllllEquidacent (bevacizumab biosimilar) / Fujifilm Kyowa Kirin Biologics, AstraZenecaCentus Biotherapeutics Announces Positive CHMP Opinion for FKB238, Biosimilar Bevacizumab (Fujifilm Kyowa Kirin Biologics Press Release) - Jul 27, 2020 - "Centus Biotherapeutics...announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the Marketing Authorization Application of EquidacentTM (Product Code: FKB238), the company’s biosimilar to Avastin® (bevacizumab), for indications including metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer, advanced and/or metastatic renal cell cancer, epithelial ovarian, fallopian tube, or primary peritoneal cancer, persistent, recurrent, or metastatic carcinoma of the cervix. The decision of the European Commission (EC) on the approval is expected in September 2020..."llllllllllLynparza (olaparib) / Merck (MSD), AstraZenecaLynparza: Regulatory decision in Japan for ovarian cancer (based on PAOLA trial) in H2 2020 (AstraZeneca) - Jul 30, 2020 - H1 2020 Results: Regulatory decision in China for BRCAm breast cancer in H2 2020 [Screenshot]llllllllllZejula (niraparib) / GSK, ZAI Lab, J&J, Takeda; dostarlimab (TSR-042) / GSKZejula + dostarlimab:Data from P2 MOONSTONE trial (NCT03955471) for 2L PROC ovarian cancer in H2 2021 (GSK) - Jul 29, 2020 - Q2 2020 Results [Screenshot]llllllllllpamiparib (BGB-290) / EMD SeronoPriority Review Granted to BeiGene’s New Drug Application of Pamiparib in Ovarian Cancer in China (GlobeNewswire) - Jul 27, 2020 - "BeiGene, Ltd...today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has granted priority review status to the New Drug Application (NDA) of pamiparib, BeiGene’s investigational inhibitor of PARP1 and PARP2, for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy."llllllllllGEN-1 / CelsionCelsion Corporation Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer (GlobeNewswire) - Jul 27, 2020 - "Celsion Corporation....announced the randomization of the first two patients in the Phase II portion of the Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian cancer. The Company anticipates completing enrollment of up to 118 patients in the third quarter of 2021. Because this is an open-label study, the Company intends to provide clinical updates throughout the course of treatment including response rates and surgical resection scores."
